Dehydroepiandrosterone sulfate DHEA sulfate; Prasterone sulfate|cas:651-48-9|西域试剂

Dehydroepiandrosterone sulfate DHEA sulfate; Prasterone sulfate,98.27%

产品编号：Bellancom-113416| CAS NO：651-48-9| 分子式：C₁₉H₂₈O₅S| 分子量：368.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-113416	￥1100.00	杭州北京（现货）
Bellancom-113416	￥1800.00	杭州北京（现货）
Bellancom-113416	￥3600.00	杭州北京（现货）
Bellancom-113416	￥5700.00	杭州北京（现货）
Bellancom-113416	￥8500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Dehydroepiandrosterone sulfate DHEA sulfate; Prasterone sulfate

产品介绍

Dehydroepiandrosterone sulfate 是具有神经活性的神经类固醇，通过影响神经元的迁移、树突的分枝化和新突触的形成，在大脑发育和衰老中发挥重要作用。

生物活性

Dehydroepiandrosterone sulfate, a neuroactive neurosteroid, plays a major role in brain development and aging by influencing the migration of neurons, arborization of dendrites, and formation of new synapses.

体外研究

Dehydroepiandrosterone sulfate (DHEAS) selectively increased the length of neurites containing the dendritic marker MAP-2.
Dehydroepiandrosterone sulfate (DHEAS) has been reported to increase neuronal excitability (firing rate) when directly applied to septal-preoptic neurons.
Dehydroepiandrosterone (DHEA) is produced in prodigious quantities by the human adrenal, principally as the 3-sulfoconjugate DHEA sulfate (DS) during intrauterine life.
Dehydroepiandrosterone sulfate (DHEAS) is generally nontoxic and lacks adverse side effects even when it is administered chronically.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

DHEAS chronic administration produces a dose-dependent effect on performance.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sixty-four male Sprague-Dawley rats, approximately 90 days of age (300-400 g).
Dosage:	5, 10, or 20 mg/kg.
Administration:	Subcutaneous injection starting 7 days post-surgery and 1 h prior to all behavioral testing.
Result:	Significantly effective in improving latency to reach the platform as compared to injured rats receiving vehicle.

体内研究

DHEAS chronic administration produces a dose-dependent effect on performance.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sixty-four male Sprague-Dawley rats, approximately 90 days of age (300-400 g).
Dosage:	5, 10, or 20 mg/kg.
Administration:	Subcutaneous injection starting 7 days post-surgery and 1 h prior to all behavioral testing.
Result:	Significantly effective in improving latency to reach the platform as compared to injured rats receiving vehicle.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (271.38 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7138 mL	13.5689 mL	27.1378 mL
5 mM	0.5428 mL	2.7138 mL	5.4276 mL
10 mM	0.2714 mL	1.3569 mL	2.7138 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.78 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.78 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.78 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.78 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明